MDGE.F Stock Overview
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.43 |
| 52 Week High | €2.84 |
| 52 Week Low | €1.50 |
| Beta | 0.85 |
| 1 Month Change | -11.96% |
| 3 Month Change | n/a |
| 1 Year Change | 15.17% |
| 3 Year Change | -49.38% |
| 5 Year Change | -77.08% |
| Change since IPO | -42.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDGE.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 1.2% |
| 1Y | 15.2% | 1.1% | 24.7% |
Return vs Industry: MDGE.F exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: MDGE.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| MDGE.F volatility | |
|---|---|
| MDGE.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDGE.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MDGE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 76 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDGE.F fundamental statistics | |
|---|---|
| Market cap | US$45.22m |
| Earnings (TTM) | -US$17.32m |
| Revenue (TTM) | US$6.46m |
7.0x
P/S Ratio-2.6x
P/E RatioIs MDGE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGE.F income statement (TTM) | |
|---|---|
| Revenue | €6.03m |
| Cost of Revenue | €1.64m |
| Gross Profit | €4.39m |
| Other Expenses | €20.57m |
| Earnings | -€16.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 72.77% |
| Net Profit Margin | -268.10% |
| Debt/Equity Ratio | 0% |
How did MDGE.F perform over the long term?
See historical performance and comparison